A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

Publisher: John Wiley & Sons Inc

E-ISSN: 1097-0142|120|13|2016-2024

ISSN: 0008-543x

Source: CANCER, Vol.120, Iss.13, 2014-07, pp. : 2016-2024

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content